Digoxin changed enzymatic pathways for sodium and potassium in heart cells.

Space and Yegnasubramanian say that the next steps will be to determine the mechanism of digoxin effect on prostate cancer cells, which support testing digoxin or other drugs that work in the same way in clinical trials as a potential prostate cancer therapy. Digoxin changed enzymatic pathways for sodium and potassium in heart cells, and according to the researchers, may also influence the same or different pathways in prostate cancer.

Notes:Funding for the research was supported by the National Cancer Institute, National Institutes of Health that made Patrick C. Walsh Prostate Cancer Research Fund at Johns Hopkins, and the National Heart, and Blood Institute is available.On Roche – Basel, Switzerland Basel, Switzerland being of one of the leading global research-focused healthcare groups in the fields of pharmaceuticals and diagnostics? As the supplier of innovative products and services for , prevention, diagnosis, prevention, diagnosis and treating diseases, the Group contributes broadly to improving? Health and quality of life of. Roche is one of the world important suppliers of diagnostics, a leading provider of medicines for cancer and transplantation and a market leader in virology. At 2005 sales by the Pharmaceuticals Division on 27, the Swiss franc the Diagnostics Division posted sales of 8.2 billion Swiss francs.